Adynxx

100 Pine Street
Suite 500
San Francisco
California
94111
United States

Tel: 415-512-7740

About Adynxx

Adynxx, located in San Francisco, California, is a clinical-stage pharmaceutical company developing a transformative technology platform addressing pain at its molecular roots – preventing the development of pain following surgery or trauma and resolving established chronic pain syndromes. Adynxx’s unique approach is to modify the course of pain rather than merely manage symptoms.
YEAR FOUNDED:
October 2007
LEADERSHIP:
Founder and CSO: Julien Mamet
CEO: Rick Orr
CMO: Donald C. Manning

15 articles about Adynxx

Adynxx Reports Third Quarter 2019 Financial Results

11/14/2019

Adynxx, Inc. announced financial results and provided a business update for the quarter ended September 30, 2019.
Adynxx Announces Notice Of Award For $5.7M In Federal Grant Funding

12/13/2018

Award intended to fund Phase 2 study of brivoligide in patients undergoing mastectomy
Adynxx and twoXAR Form Collaboration to Discover and Develop Treatments for Endometriosis

11/15/2018

Drug Development Approach Combines twoXAR’s Artificial Intelligence-Driven Discovery Technology with the Adynxx Team’s Development Experience
Alliqua BioMedical Inc. and Adynxx, Inc. Announce Merger Agreement to Create NASDAQ-listed Clinical-Stage Pharmaceutical Company with a Focus on Pain and Inflammation

10/12/2018

Alliqua BioMedical, Inc. and Adynxx, Inc. today announced that they have entered into a definitive merger agreement under which the stockholders of Adynxx would become the majority owners of Alliqua's outstanding common stock on a fully-diluted basis.
Adynxx Announces Results of the ADYX-004 Phase 2 Study of Brivoligide (AYX1) for the Treatment of Post-Surgical Pain

4/12/2018

Brivoligide reduced post-surgical pain, opioid use and time to achieve mild pain in an underserved patient population that suffers from inadequate pain relief following surgery
Adynxx Completes Enrollment In ADYX-004, A Phase II Study Of Brivoligide (AYX1), Lead Compound For The Treatment Of Post-Surgical Pain

10/4/2017
Adynxx Initiates ADYX-004, A Phase II Study Of AYX1, Lead Compound For The Treatment Of Post-Surgical Pain

3/1/2017
Adynxx Release: Biotech Announces Closing Of Series B Financing

1/10/2017
Adynxx Completes Patient Enrollment In Phase 2 Dose-Ranging Study Of AYX1 For Prevention Of Post-Surgical Pain

5/14/2015
Adynxx Initiates Phase 2 Dose-Ranging Study Of AYX1, Lead Compound For The Prevention Of Post-Surgical Pain

7/16/2014
Adynxx Completes Patient Enrollment in Phase 2 Clinical Study of Lead Therapeutic for Prevention of Pain, AYX1

9/5/2013
FDA Grants Fast Track Designation to Adynxx Lead Compound AYX1

7/17/2013
Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain

2/25/2013
Lead Therapeutic Candidate for Treatment of Pain from Adynxx, AYX1, Well-Tolerated in Phase 1 Clinical Study

9/5/2012
Adynxx Completes Enrollment in Phase 1 Clinical Study of Lead Therapeutic for Treatment of Pain, AYX1

8/7/2012